Literature DB >> 34218411

Clinicodemographic pattern and treatment outcome of Behcet's disease cases presenting in a tertiary eye center of Nepal.

Anu Manandhar1, Buddhi Prasad Paudyal2.   

Abstract

PURPOSE: To know the clinical and demographic pattern, and the outcome of treatment of Behcet's disease (BD) cases in Nepal
METHODS: Retrospective series of all the cases of BD who had come over the period of 12 years (Jan 2007-Dec 2015) Tilganga Institute of Ophthalmology. RESULT: Twenty-one cases were included, 17 (81%) male and four (19%) female. Mean age was 28.88 ± 9.18 years. Mean follow-up period was 3.6 ± 2.6 years. All had nongranulomatous panuveitis. Hypopyon was seen in 13 (61.9%) cases. Small retinal infiltrates in 13 (61.9%) cases and retinal vasculitis in ten (47.6%) cases were seen. Cataract (in 13, 61.9%) and optic atrophy (in 11, 52.4%) cases were present. Oral ulcer was present in 20 (95.2%), genital ulcer in 15 (72%), and skin lesions in 13 (62%) cases.
CONCLUSION: BD affected mainly the most active age group and was predominant in male. Optic atrophy was the leading cause of irreversible vision loss. Despite being a less common condition, BD should be considered in the differential diagnosis of panuveitis cases in the Nepalese population.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Behcet’s disease; Hypopyon; Nepal; Optic atrophy; Panuveitis

Year:  2021        PMID: 34218411     DOI: 10.1007/s10792-021-01845-7

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  3 in total

1.  Behçet's disease: an account of three cases.

Authors:  B Paudyal; M Gyawalee; A Manandhar; K Sigdel
Journal:  J Nepal Health Res Counc       Date:  2012-09

2.  Behçet's Uveitis.

Authors:  Ilknur Tugal-Tutkun
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

3.  Neuro-Behçet disease with demyelination and gliosis of the frontal white matter.

Authors:  C Yamamori; H Ishino; T Inagaki; H Seno; M Iijima; I Torii; T Harada; S Morikawa
Journal:  Clin Neuropathol       Date:  1994 Jul-Aug       Impact factor: 1.368

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.